The President and Personalized Medicine.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 263
- By:
- Publication type:
- Article
Works matching IS 21660166 AND DT 2016 AND VI 5 AND IP 6
Results: 19
1
2
Phase 3 Evidence for New Standard in Elderly Glioblastoma Patients.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 261
- Publication type:
- Article
3
Combination Immunotherapy Makes Progress in Advanced Melanoma.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 260
- Publication type:
- Article
4
Alectinib May Constitute New Frontline Treatment for ALK-Positive NSCLC.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 259
- Publication type:
- Article
5
Addition of Bcl-2 Inhibitor to MM Regimen Produces Promising Responses in Relapsed/Refractory MM.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 258
- Publication type:
- Article
6
Atezolizumab Could Be Start of "Seismic Shift" in Treatment of Metastatic Urothelial Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 257
- Publication type:
- Article
7
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 256
- Publication type:
- Article
8
Opportunities for Shared Decision-Making in Clinical Practice.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 252
- Publication type:
- Article
9
Out-of-Pocket Costs Linked to Compliance with Oral Oncologics.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 251
- Publication type:
- Article
10
New Paradigm: Matching Therapy to Molecular Alterations.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 250
- Publication type:
- Article
11
Refining Use of CAR-T in ALL.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 249
- Publication type:
- Article
12
"Smart Bomb" Drug: Rova-T Promising in SCLC.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 248
- Publication type:
- Article
13
AML Vaccine Induces Immunologic Responses in Phase 2 Study.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 246
- Publication type:
- Article
14
Targeting CD38 Leads to Responses in Relapsed/Refractory MM.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 245
- Publication type:
- Article
15
Liquid Biopsies Have High Correlation with Tissue Biopsy for Genetic Mutations.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 244
- Publication type:
- Article
16
RAF Family Inhibitor Has Preliminary Activity in Multiple Types of Tumors.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 242
- Publication type:
- Article
17
"Check"-ing the Data: A Review of Immune Checkpoint Inhibitor Biomarkers.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 234
- By:
- Publication type:
- Article
18
Increased Risk for Serous/Serous-like Endometrial Cancer Found in BRCA1 Carriers.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 241
- By:
- Publication type:
- Article
19
Presenting Emerging Data and Calling for Molecular Tumor Board Case Studies.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 232
- By:
- Publication type:
- Article